UA is widely present in various plant sources, including medicinal plants, fruits, herbs, etc., as a pentacyclic triterpenoid with a characteristic pentacyclic structure and hydrophobic tail, defining its unique features. It is chemically represented by the formula C₃₀H₄₈O₃ (Figure 4) (Ikeda et al., 2008). Its stability and capacity to interact with different biological processes in the body are due to this structure (Liu et al., 2021). The lipophilic character of UA contributes towards its oral bioavailability. The chemical structure of the substance is crucial because of its interaction with the cell membrane which allows the gastrointestinal tract to absorb it (Alam et al., 2021). Due to its potential anti-cancer activity, UA has gained lots of attention, especially in the context of gastrointestinal tumors (Pięt and Paduch, 2019; Limami et al., 2023). The structure-activity relationship for terpenoids and their derivatives has been described at the molecular level by the development of a 3D-QSAR model (Perestrelo et al., 2019). The development of machine learning algorithms has facilitated explorations in this area. A comparative molecular field analysis (CoMFA) model, for example, displays an excellent cross-validation correlation coefficient (q2) of 0.54 and a regression correlation coefficient (r2) of 0.86 (Stitou et al., 2019). Since T9 and B42 exhibit good binding affinities and fall within the conventional limits of all filters, they have been designated as the greatest hits (Yadav et al., 2018). The cytotoxic activity of UA analogs against human lung (A-549) and CNS (SF-295) cancer cell lines was predicted using QSAR models. The regression coefficient (r2) and cross-validation regression coefficient (rCV2) of the QSAR model were found to be 0.85 and 0.80, respectively, for cytotoxic activity against the human lung cancer cell line (A-549) (Kalani et al., 2012).

Orally bioavailable, UA is mostly absorbed in the gastrointestinal tract. Since UA is lipophilic, it can pass through cell membranes and be absorbed more easily (López-Hortas et al., 2018; Mlala et al., 2019). After absorption, UA is disseminated throughout the body, even to regions impacted by gastrointestinal malignancies. Tissue permeability and protein binding are two variables that could affect its distribution (Mlala et al., 2019; Wang et al., 2021). The conversion of UA involves hepatic metabolism. Water-soluble metabolites are formed in part by phase II conjugation processes such as glucuronidation and sulfation. Biliary excretion is the main mechanism by which UA and its metabolites are removed from the body. Prolonged UA presence in the system could be caused by enterohepatic circulation (Yu et al., 2020).

Esophageal cancer (cancer in esophagus) serves as a global concern in cancer research and is challenging due to its unpredicted disease pattern. In the current scenario, advanced molecular techniques are needed to increase our understanding of diagnostic, disease prediction and treatment approaches (Lagergren et al., 2017). In addition to challenges associated with diagnostic and treatment practices, there are further challenges in controlling the progressive occurrence of GI cancers. Cancer cases are rapidly increasing throughout the world, with reports emerging from regions such as Africa, Eastern Europe and Eastern Asia. Cancer epidemiology-based studies helps to study the prevalence, incidence, and mortality effects. In the case of esophageal cancer, two types of epidemiological patterns are observed: namely, adenocarcinoma and squamous cell carcinoma. Squamous cell carcinoma of the esophagus is more common compared to adenocarcinoma; with case studies indicating that approximately 90% of cases are squamous cell carcinoma. Esophageal cancer is majorly reported in aged people and rarely reported in the younger generation. Squamous cell carcinoma cases are found in excessive alcoholic and tobacco consumption persons while adenocarcinoma is related to gastroesophageal effects like obesity (Rustgi and EI-Serag, 2014). Reports based on molecular studies found mutations play an important role in the progressive development of esophageal cancer. Such mutations cause adverse changes in the signaling pathways of the vital gene and have a role in tumour supersession. CDKN2A genes encode tumor suppressor protein p16 and mutations in such gene cause gene alterations in CDKN2A, which is further responsible for disease progression (Secrier et al., 2016; Thrift, 2016). Similar results have been reported for p53 protein-coding genes, i.e., TP53, in the case of squamous cell carcinoma and adenocarcinoma. The p53 protein has a significant role in tumor suppression and defects in its encoding gene TP53, leading to progressive tumor formation in adenocarcinoma and squamous cell carcinoma both conditions (Song et al., 2014).

Cellular migration, proliferation and survival are controlled by epidermal growth factor receptor (EGFR) pathways. In esophageal adenocarcinoma, EGFR genes are often overexpressed and unregulated. The signaling pathways of EGFR promote metastases, angiogenesis and tumor growth. Therefore, targeting these are one of the approachable ways of cancer treatments (Liu et al., 2017). EGFR signaling pathway associated with PI3K, AKT, mTOR cascade and uncontrolled regulation in these proteins lead to enhanced cellular proliferation, exhibits resistance to treatment therapy, and develop cancer in the body (Xie et al., 2020). Esophageal adenocarcinoma initiation is linked with the Wnt/β-catenin pathway. WNT signaling pathway dysregulation promotes the excessive growth of tumor cells, and the aberrant activation of β-catenin facilitates metastasis by translocating to the nucleus. Targeting the Wnt/β-catenin signaling for treatment is considered a promising therapeutic approach for esophageal cancer (Hassanabad et al., 2020). It has been reported that Notch signaling plays a role in esophageal cancer as it assists in the tumor formation. In a preclinical study, inhibitors of the Notch signaling pathway have demonstrated anti-tumor activity against esophageal cancer. Therefore, targeting the Notch signaling pathway is considered a promising therapy for esophageal cancer (Wang et al., 2014).

Exploring the application of molecular biomarkers in the diagnosis and early detection of esophageal cancer holds promise as an effective approach towards cancer management. The altered DNA methylation patterns, microRNA expression, and ctDNA have emerged as crucial biomarkers for assessing risk factors, early detection, and monitoring of treatment response. Additionally, molecular subtyping may also support in identifying patients who are prone to benefit from specific treatments, such as immunotherapy and neoadjuvant chemotherapy (Shapiro et al., 2015). Although much progress has been made, barriers exist that make it difficult to translate molecular data for clinical use. Heterogeneity within the tumors of the esophagus, tumor microenvironment dynamics, and interpatient variability warrants the need for an extensive view of the molecular landscape that can be used for rational treatment decisions. Integration of molecular profiling into everyday clinical practice needs to have standardized methodologies, robust biomarkers, and collaborative research efforts to validate findings and ascertain clinical utility. Molecular research reoriented has reshaped our understanding of esophageal cancer, being the source of understanding its mechanisms, classification, and treatment options. Through clarifying key molecular abnormalities, researchers have outlined early detection biomarkers, prognostication biomarkers, and biomarkers for targeted therapy selection. Recent progress in molecular characterization has deeply refined esophageal cancer, allowing more focused diagnoses and individualized treatment strategies. Molecular subtypes defined by gene expression profiles are distinct and have specific biological features and outcomes (Sheikh et al., 2023).

Helicobacter pylori is a bacterium associated with the stomach lining and it is one of the risk factors associated with gastrointestinal cancer. It causes chronic gastritis and peptic ulcers which leads to cancer of the stomach by creating an environment for the carcinogens (Chen et al., 2024). Furthermore, dietary habits such as smoking, and consuming salty food, tobacco, and alcohol consumption increase the potential risk for gastric cancer.

The location of the tumor and the various stages of gastric cancer influence its clinical representations. Several non-specific symptoms such as nausea, loss of appetite, bloating, abdominal discomfort, etc., May count under the early symptoms of gastric cancer. With the progression of cancer, more pronounced symptoms may appear such as persistent vomiting, weight loss, fatigue, anemia, etc. It is very important to recognize these early signs for better treatment (Shin and Park, 2024). For the diagnosis of such conditions, there are several approaches available in the clinical settings from imaging to endoscopy following biopsy. The direct visualization of the stomach lining can be achieved using endoscopy for the appropriate samples for biopsy. Several advanced techniques for imaging including endoscopic ultrasound, computed tomography, magnetic resonance imaging, etc., Allow the detection of the extent of tumor invasion and its metastasis to the adjacent tissues and different organs (Huang et al., 2023). The samples which are taken for the biopsy may be subjected to molecular characterization for the identification of genetic alterations, treatment, and prognosis. Overall strategies for the treatment depend on the patient’s stage of cancer and current health condition whether it is required to remove tissue surgically or following treatment with chemotherapy (Alsina et al., 2023). Usually, for the treatment of gastric cancer, chemotherapy is commonly employed using drugs such as fluoropyrimidines, platinum-based agents and taxanes. The targeted therapies are employed for molecular pathways which are actively associated with the progression of tumor. Trastuzumab is one of the best examples, it is a monoclonal antibody which specifically targets the HER2/neu receptor involved in gastric cancer (Hui et al., 2024).

As far as immunotherapy is concerned, immune checkpoint inhibitors that particularly target protein PD-1 or its ligand PD-L1 (programmed cell death protein) are widely employed due to their promising results (Zou et al., 2019; Zou et al., 2024). Moreover, current studies suggest that UA possesses different pharmacological properties that can inhibit gastric cancer development.

Colorectal cancer (CRC) is also the most frequent and second most lethal cancer in the world. It arises from the colonic mucosal epithelia lining causing irregular proliferation of colonocytes (Sachdeo et al., 2020; Sung et al., 2021; Xi and Xu, 2021). In the calendar year 2020, around 1.9 million new cases and 930,000 deaths were reported with the projection of 3.2 million novel cases per year followed by 1.6 million deaths. This report showed an increment of around 60% in new cases and 73% in deaths up to the end of 2040 (Biller and Schrag, 2021; Sawicki et al., 2021). Preclinical studies have revealed the promising efficacy of UA against CRC by inhibiting its proliferation and induction of apoptosis (Chen et al., 2022). Due to its anti-inflammatory properties, UA inhibits the expression of enzymes and cytokines responsible for the inflammation in CRC. Additionally, it contributes to the reduction of oxidative stress through its antioxidant activities, which play a role in CRC development. Antioxidant activities of UA such as free radical scavenging activity reduce the oxidative damage to the DNA (Lin et al., 2013; Zhao M. et al., 2023). Zhang and colleagues demonstrated that UA prevents the growth of malignant cells by modulating the miR-140-5p (increasing)/TGF- β3 (decreasing) axis, which is closely linked to the blockade of the Wnt/β-catenin signaling pathway, potentially inhibiting cell growth (Zhang et al., 2024). Conclusively all the in vitro studies concludes that UA can regulate the Wnt/β-catenin, PI3K/Akt, and NF-κB signaling pathway, all of which play significant roles in CRC (Lin et al., 2013; Chan et al., 2019).

One area of particular interest is the effect of UA on pancreatic cancer, which is known to be highly aggressive and often renders fatal malignancy due to limited treatment options. Several studies have explored the potential of UA in inhibiting the growth and progression of pancreatic cancer cells both in vitro and in vivo (Prasad et al., 2016; Khwaza et al., 2020; Lin et al., 2020; Lin et al., 2020). UA has been found to exhibit its anticancer effects by inducing apoptosis, and inhibiting migration and invasion (Lin et al., 2020; Hashem et al., 2022). UA has been demonstrated to modulate various signaling pathways implicated in pancreatic cancer development and progression. For instance, it can suppress the activation of NF-κB, a transcription factor involved in inflammation and cancer, thereby reducing the expression of pro-inflammatory and pro-survival genes (Li et al., 2021). Furthermore, UA has been shown to inhibit the PI3K/Akt/mTOR pathway, which is frequently dysregulated in pancreatic cancer, leading to promotion of cell growth and survival (Zafar et al., 2022). In preclinical animal models of pancreatic cancer, UA has exhibited promising antitumor effects, leading to reduced tumor growth and improved survival outcomes (Li et al., 2021). Despite some encouraging findings, further research is needed to fully elucidate the therapeutic potential of UA in pancreatic cancers. Further clinical trials for evaluating the efficacy and safety of UA either alone or in combination with conventional therapies are required (Zafar et al., 2022). Synergistic studies of UA with other phytochemicals to tackle pancreatic cancers could also be evaluated. Also, studies associated with investigating the optimal dosage, formulation, and route of administration of UA are essential for its successful therapeutic development (Wang et al., 2021).

Studies have shown the anti-cancer properties of UA against hepatocellular carcinoma (HCC), both in vitro and in vivo (Sureda et al., 2021). UA has been found to exert its effects by multiple signaling pathways including inhibition of STAT3/PD-L1 signaling (Kang et al., 2021b). One of the key physiological aspects is the induction of apoptosis by regulating caspase-3, in liver cancer HepG2 cells and mice models (Ma et al., 2021). By triggering apoptosis, UA can inhibit the uncontrolled growth and proliferation of cancer cells, thereby suppressing tumor progression (Limami et al., 2023). Moreover, UA has been shown to inhibit the migration and invasion of liver cancer cells, which are essential steps in metastasis, and the spread of cancer to other parts of the body (Liang et al., 2021). This anti-metastatic effect is crucial for preventing the aggressive spread of liver cancer and improving patient outcomes. Studies associated with UA have been reported to possess anti-inflammatory properties, which are particularly relevant in liver cancer as chronic inflammation is a major risk factor for the development of HCC (Luan et al., 2022). A study has shown that UA significantly reduced the levels of inflammatory parameters IL-1β, IL-6 and TNF-α in mouse tissues. By reducing inflammation, UA helps to mitigate the progression of liver cancer (Zhao M. et al., 2023). Furthermore, UA has been shown to modulate various signaling pathways involved in liver cancer development and progression. A research study found that UA extracted from Ludwigia hyssopifolia can inhibit the activation of the PI3K/Akt/mTOR pathway, which is frequently dysregulated in liver cancer and promotes cell survival and proliferation (Liu et al., 2024). By targeting these signaling pathways, UA can exert its anti-cancer effects and inhibit the growth of liver tumors. Preclinical studies in H22 tumor-bearing mouse models have demonstrated the efficacy of UA in reducing tumor growth and improving survival outcomes (Wang et al., 2021). However, further research is required to further understand the therapeutic potential, evaluate the safety and efficacy of UA in liver cancer and optimize its use in clinical settings (Sun et al., 2020).

In the current scenario, NPs can be considered as a potential option for the treatment of various types of cancers that can accomplish various objectives limiting negative impact (Li et al., 2019). Nanoparticles can enhance drug delivery kinetics and the bio-distribution properties of medications (Ravindran et al., 2018). Novel NPs like nanobubbles have been created to enhance the accuracy and effectiveness of cancer diagnosis and treatment by delivering drugs to specific targets (Nittayacharn, et al., 2019).

Nanoparticles are essential in advancing the treatment of GI cancer. Nanoparticle-based research has shown promising results in targeting a wide range of cancer types due to its distinct characteristics (Kanaoujiya et al., 2022). Nanotechnology advancements, diagnosis and treatment are becoming more accessible. Throughout the years, a wide range of these particles have been utilized for diagnosing and treating cancers in the GI tract (Liang et al., 2022). Nanoparticle treatments offer numerous benefits in therapy for cancer, including their ability to carry a large amount of medication, pinpoint active tumors, and regulate drug release. Nanomaterials have been identified for potential use in treating gastric cancer shown in Figure 5 (Yao et al., 2020). Quantum dots have the potential to significantly contribute to the diagnosis of various cancer types through ongoing research on quantum dots probes (Khan et al., 2023). These are commonly used in identifying malignant tumors as a dependable sign. Examining the main components of the tumor stroma using a wide range of biomarkers to assess specific medical results in GI cancer (Wang H. et al., 2024).

In addition to quantum dots, dendrimers could also have a significant role. These are intricate branched artificial structures with multiple concentric layers. Various proteins can be identified through dendrimers. Furthermore, these can be utilized for imaging through Magnetic resonance imaging and Near-infrared spectroscopy modalities using a single probe (Fernandes et al., 2022). These NPs are designed with unique features tailored for use. Moreover, they can retain the drugs that fight cancer through encapsulation or chemical bonding with their surface functional groups (Joudeh and Linke, 2022).

Moreover, when discussing certain metal NPs used for diagnosing and treating a particular disease, iron oxide NPs are considered excellent examples as they possess distinct magnetic responsiveness, surface functionalization, and biocompatibility. The surface of these NPs can be modified with specific ligands that can identify receptors over-expressed on the targeted cell for precise drug delivery (Figure 6) (Qiao et al., 2023). Alternatively, these NPs can be used for diagnosis and monitoring through imaging. The magnetic properties of these NPs enhance contrast for precise tumor detection. Credit to these distinct characteristics, they could be promising options for improving the effectiveness of treatments for GI tract cancer. In addition to these nanostructures, carbon nanotubes, nano-shells, nano-emulsions, liposomes, and polycaprolactone NPs are equally significant (Baranwal et al., 2023).

As far as GI mucosal permeability is concerned, UA has a low oral absorption rate and is poorly permeable. Hence, nanoformulations of UA are given intravenously to enhance drug delivery to the tumor. These formulations prioritize surface functional properties, stability, and size to enhance permeability and retention. Various nanoformulations have been researched over time, such as polymer micelles of UA, UA-liposomes, UA-nano-emulsions, UA-nanoparticles, Chitosan nanoparticles, polylactic acid nanoparticles, UA nanocrystals, etc. (Israel, 2018).

In this scenario, polymer micelles containing UA were created using mPEG-PLA (methoxy polyethylene glycol poly lactic acid) to target liver cancer cells. The delivery system displayed remarkable stability with a smooth and spherical shape, showcasing controlled release at various pH levels (7.5 and 5.5), leading to improved accumulation in tumors. This system inhibited HepG2 cell proliferation without harming normal hepatic cells and even enhanced normal hepatic cells at very low concentrations, indicating the potential of a UA-loaded polymer micellar delivery system for treating hepatic cancer (Zhou et al., 2019).

Enhanced stability with a slower release rate was noted in the Polyethylene glycol modified UA liposomes in comparison to regular liposomes. With a ratio of 3:2:5:50 UA, PEG, Cholesterol, and soy lecithin in PEG-modified UA liposomes, a uniformly spherical shape was achieved with a high encapsulation rate compared to regular liposomes. As a result, the liposome becomes harder, leading to enhanced membrane stability and preventing abrupt drug release (Zhao et al., 2015). Many nano-formulations have developed to enhance stability and improve the efficiency of drug release. Minimizing accumulation at non-targeted sites ultimately improves the clinical efficacy of UA. Liposomes could imitate cell membranes, enhancing the drug-delivery process (Lee et al., 2020). Furthermore, they struggle with temperature changes that can disrupt drug permeability and cause leakage. Just like micelles, there is a unique core-shell structure, but they have the lowest drug-loading capacity (Siboro et al., 2020). Nanocrystals exhibit high drug-loading capability and scalability, making them suitable for a wide range of applications (Jarvis et al., 2019; Naseema et al., 2021). In addition, nanoemulsions have unique properties and are highly responsive to environmental changes. Together, it is evident that each nano-formulation presents unique obstacles and benefits, with a focus on enhancing UA delivery methods for improved clinical results (Naseema et al., 2021).